programmed cell death 1 ligand 1

Home
Ligands
programmed cell death 1 ligand 1 (Human)

GtoPdb Ligand ID: 9606

Abbreviated name: PD-L1

Synonyms: B7 homolog 1 | B7-H1 | PDL1 | programmed death ligand 1

Compound class: Endogenous peptide in human, mouse or rat

Comment: This is one of the ligands for the PD-1 receptor. It is a single-pass type I membrane protein. The PD-L1/PD-1 interaction is an established immune checkpoint. Both the ligand and receptor are targets for novel immuno-oncology therapeutics, as over-expression of either of these proteins is a mechanism used by tumour cells to evade immune detection and destruction. Already the target of approved immunotherapeutics in the form of monoclonal antibodies, small molecules targeting the PD-1/PD-L1 checkpoint are now in development to address the shortcomings associated with the current antibody therapies (including, poor susceptibility rate to single immune checkpoint pathway inhibitors, long half-life of antibodies and association with the development of adverse events, problems connected to the requirement for intravenous infusions) [7,16].

Species: Human

No information available.

No information available.

Summary of Clinical Use
PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [6,9,18] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Additional reading: [12] and [11].

Summary of Clinical Use

PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [6,9,18] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Additional reading: [12] and [11].